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Despite  the  numerous  clinical  and  experimental  investigations  on 
antipneumococcic  serum,  its  exact x61e  in  pneumococcus infection  is 
still  relatively  obscure.  The  purpose  of  this  communication  is  to 
report  experiments  which  show  that  antipneumococcic  serum  con- 
tains  an  important  therapeutic  factor,  which  is not  antibacterial  in 
character. 
The current opinion is that the protective antibody in the serum is antibacterial. 
In 1915, Bull (1), in studying the effect of serura on pneumococcus septicemia in 
rabbits, suggested that the protective antibody acts in vivo by virtue of its agglu- 
tinating power, and that the survival or death of the animal depends upon the 
destruction of the agglutinated organisms by the phagocytic cells of the blood and 
tissues.  Cole (2), Dochez and Avery (3), and others showed that in pneumococ- 
cus-infected exudates and sera as wall as during the growth of the organisms in 
vitro, there is present a  soluble  substance, which  can combine with the immune 
bodies of the serum, and thus detract from its action against the organisms.  The 
later studies of Heidelberger and Avery (4), and others on the chemical constitu- 
tion of pneumococcus protoplasm had established this soluble  specific substance 
as the chief capsular constituent, a carbohydrate fraction of the organism respon- 
sible for its type specificity and virulence.  The subsequent work of Felton and 
Bailey (5) indicated that this purified carbohydrate soluble specific substance was 
capable of neutralizing the protective antibody.  Thus it appeared that the func- 
* I  am indebted to Professor William H. Park for his continued interest and 
stimulating criticism throughout the course  of this work.  I  also wish to thank 
Mr.  M. Percoco, Mr. H. Ferris, Miss A. Lewis,  and Miss B.  Goldfarb for theic 
technical assistance. 
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tion of antipneumococcic serum is to combine with the soluble specific substance 
present either free in the circulation or on the intact organism.  This concept of 
the mechanism, however, fails to explain all the known facts. 
For instance, further investigations (6) showed that in addition to the antibody 
neutralizable  by the  soluble  specific  substance  (SSS),  antipneumococcic serum 
contains  type-specific antibody which  is  not  thus  neutralized.  This  fact  was 
established by demonstrating first, that a certain amount of type-specific protec- 
tive antibody remains in antipneumococcic serum after complete precipitation of 
the  anti-SSS precipitins,  and  second,  that  this  residual  type-specific protective 
antibody is neutralized neither by additional SSS nor by absorption with heterol- 
ogous pneumococci; it is, however, definitely absorbed with the homologous pneu- 
mococci.  Recently, Ward  (7)  questioned  the validity of this  assumption first 
because he  felt  that  it  appeared  improbable  that  the protective  action of the 
serum should be due to several antibodies, and secondly because he was able to 
show that a Type III serum  apparently completely precipitated with  Type III 
SSS, still had a certain amount of antibody, which must have escaped precipita- 
tion, and was capable of specifically neutralizing the in vitro, specific antiphago- 
cytic effect of small amounts of SSS.  With regard to the first contention, it is not 
at all improbable that the antibacterial effect of a serum may depend on several 
antibodies reacting with different antigenic components of the organism.  Actually 
the work of Enders  (8),  and more recently that  of Wadsworth and Brown  (9) 
indicate that a type-specific substance other than the so called SSS does exist in 
Pneumococcus Type I.  Whether or not the same is true in the case of Pneumo- 
coccus Type III is still unknown and, therefore, the comparison is  not warranted. 
With reference to Ward's repetition of the experiments,  referred  to above  (6), 
it must be stated that he failed to add more SSS to the supernatant liquid of his 
apparently completely precipitated serum, before testing its neutralization of the 
antiphagocytic effect of small amounts of SSS.  What the results would have been 
then is, of course, impossible to predict, although theoretically, the solutions, in 
which the residual type-specific mouse protective antibody was demonstrated (6), 
because they contained a large excess of SSS would rather be expected to be anti- 
phagocytic in  vitro.  Nevertheless,  it  is  interesting  to note  that  Ward's other 
experiments  suggested that  the anti-SSS action is not the only function of the 
serun'L 
However, whether  there be one,  two, or more type-specific antibodies,  their 
action is nevertheless chiefly antibacterial, since they can be specifically absorbed 
with the intact organisms, and their in vivo r61e may still come under the agglutinin 
effect as conceived by Bull (1).  Yet the nature of the factors causing the toxemia 
and  death  of pneumococcus-infected animals  remains  obscure.  Certainly  the 
mere  presence  of  the  organisms  as  innumerable  microscopic  particles  cannot 
account for this effect.  Theoretically, therefore, it has been assumed for a long 
time that the breakdown of the organisms in vivo gives rise to toxic substances. 
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is apparently per se non-toxic to mice, rabbits, or human beings.  1  The studies of 
Rosenow (10),  Cole  (11),  and others on pneumococcus autolysates showed that 
while  these  produce anaphylactic-like  reactions  in  animals,  they could  not  be 
correlated with the signs of toxemia in pneumococcns infection.  In the past few 
years, Parker  (12)  has described certain toxic substances obtained by anaerobic 
autolysis  of  concentrated  pneumococcus  suspensions.  The  toxic  principles  in 
these autolysates are capable of producing necrosis when injected intracutaneously 
and death associated with hemorrhagic  pulmonary lesions when injected intra- 
tracheally into guinea pigs.  These toxins are species-specific  and can be neutral- 
ized by heterologous anti-autolysate serum.  Parker  and McCoy (13)  reported 
the production of potent a.ntitoxic serum in horses.  However, it appeared that if 
this toxin prepared in vitro by Parker played any part in the in vivo process, that 
the antitoxic serum should act not only on a lesion produced by the artificial toxin, 
but should exert a definite effect on the course or outcome of the natural infection 
as well.  This problem was investigated using the dermal pneumococcic lesion of 
rabbits reported by Zinsser  (14) and later studied in  detail by Goodner (15),  as 
it seemed to be the most suitable,  available type of experimental pneumococcus 
infection, particularly since its course and pathology (Rhoads and Goodner (16)) 
resemble so greatly that of pneumococcus pneumonia in man.  It appeared from 
this study (17) that the antitoxic serum of Parker, when used by itself or in asso- 
ciation with a so called subeffective dose of antibacterial serum, had no apparent 
effect on the progress of the pneumococcus infection in rabbits.  For this  reason 
it would seem that the anaerobically isolated toxin is probably merely a product of 
in vitro autolysis and not actually formed in the course of pneumococcus infection. 
The late Dr. E. J. Banzhaf, similarly interested in producing a serum that might 
perhaps be antitoxic as well as antibacterial, injected horses intramuscularly with 
pneumococcus broth  culture filtrates  as well as with  the sedimented organisms 
intravenously.  He assumed  that  in  case  pneumococcus broth  cultures  should[ 
contain a toxin, which, however, is not readily demonstrable on account of a prob- 
able rapid transformation into a toxoid stage, it might, nevertheless, be possible 
to prepare an antitoxin if they were used  for immunization.  Banzhaf's prelimi- 
nary laboratory tests with sera thus produced indicated that some rabbits could be 
protected  with  quantities,  in which the number of mouse protective  units was 
surprisingly low.  He subsequently very kindly submitted to me several samples. 
of this serum for further study, the results of which are included in this report. 
The following experiments deal with the demonstration  of the pres- 
ence or absence of therapeutic agents in antipneumococcic serum which~ 
1 The author injected four volunteers intramuscularly with as much as 5 rag. 
of Type I  SSS (the equivalent of 200 to 500 cc.  of culture)  without any harm- 
ful effects in three; one man, who had demonstrable aggiutinlns for Type I pneu- 
mococcus in his blood, and was probably hypersensitive, had a rise of temperature 
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are not antibacterial  in character.  For this  study,  the dermal pneu- 
mococcic lesion of rabbits appeared to be the most suitable,  available 
experimental  pnettmococcus infection. 
EXPERIMENTAL 
Pneumococcus Culture.--A 5 per cent blood broth culture of a fully virulent (i.e. 
one to five diplococci, as determined by colony count in poured plates, killed mice 
in 3 days or less)  Type I  Pneumococcus was  used in all the experiments.  The 
culture was maintained in this state of virulence and supplied for each experiment 
by Miss Georgia Cooper of the New York  City Department of Health Research 
Laboratories, to whom I  am greatly indebted. 
The Dermal Pneumococcic Lesion in the Rabbit.--Adult  rabbits weighing 1500 to 
2000 gm. were used.  The abdominal hair was removed with electric clippers the 
day before injection.  1 cc. of an 18 hour blood broth  culture was diluted with 1 
or 2  cc.  of broth  to match a  turbidity  standard,  so as to yield approximately 
200,000,000  diplococci per cc.  The further dilutions were also made with broth, 
using a fresh pipette for each dilution.  0.1 cc. of a 1-100 dilution of the standard- 
ized  culture  was  injected  intracutaneously  into  each  rabbit.  The  number  of 
organisms injected were checked each time by a  colony count in poured blood 
plates. 
Rectal  temperatures  were  taken  before  the  injection  and  daily  thereafter 
throughout the duration of the experiment.  Blood cultures from the marginal ear 
vein were taken daily from each rabbit.  The lesions were measured every day 
noting  the  size,  edema,  erythema,  hemorrhage,  and  necrosis.  Lesion  cultures 
were not done routinely because only a positive culture was considered significant, 
and  because  the  elimination  of the  necessary manipulation  was  deemed  more 
important as regards these experiments than the additional data that might have 
been obtained.  All rabbits were thus observed for at least 10 days.  Each dead 
rabbit was autopsied and cultures were taken from the heart's blood and from the 
brain. 
Comparison of the Therapeutic Effect of Standard Serum and That Pre- 
pared by Intravenous Injection of Organisms and Intra- 
muscular  Injection  of  Broth  Culture  Filtrate 
The purpose of this  experiment  was to determine,  in a  preliminary 
way,  whether  or not  the  antiserum  prepared  by immunization  with 
organisms and broth culture filtrates was therapeutically more effective 
in rabbits than the standard serum, prepared by intravenous injections 
of sedimented  organisms only. 
In  this,  as  well  as  in  the subsequent  experiments,  the  serum was adminis- 
tered intravenously 6 to 7 hours after the intracutaneous injection of the culture ALBERT  B.  SABIN  535 
rather than at 24 hours, as Goodner had done in his studies, because it appeared 
more suitable for comparative purposes.  The virulence of the culture was such 
that, with the dose used, of forty untreated rabbits in various experiments, none 
survived; furthermore at 24 hours  the disease is frequently very far advanced, 
some of the rabbits dying within 48 or 72 hours; at 6 hours, however, the lesion is 
very slight and the blood culture is positive, so that the effect of the serum can 
be noted not only on the outcome of the disease but on the progress and develop- 
ment  of the lesion as well.  It is important to note here that protective doses 
administered at 6 hours do not necessarily influence the full development of the 
lesion. 
TABLE  I 
Therapeutic Effect  of Standard  Antipneumococcic Serum and Serum Prepared by 
Injections of Organisms and Broth Culture Filtrates 
Therapy 
None 
~tandard  Serum  8 
Type I 
~erum  2321 Type I 
CC. 
0.38 
5.0 
5.0 
0.5 
0.5 
Dose 
ra,p.u.* 
300 
300 
300 
30 
30 
Hrs. after 
culture 
7 
7 
24 
7 
24 
No. of  rabbits 
used  No. survived 
* M.p.u., mouse protective units.  The mouse protective unit is ten  times the 
smallest amount  of antiserum, which protects a  majority of mice for 96 hours, 
when it is injected intraperitoneally simultaneously with 100,000  fatal doses of a 
fully virulent culture. 
From previous experiments it  was  known  that  300  mouse  protective units 
(m.p.u.) of standard Serum 8 were insufficient for the protection of a majority of 
rabbits receiving this dose at 6 hours after infection.  Serum 2321,  produced by 
intravenous injection of organisms and intramuscular injection of broth culture 
filtrate, was obtained from a horse that had been under immunization for a rela- 
tively short time and its mouse protective potency was rather low.  In this experi- 
ment four rabbits were untreated; four received 300 units of Serum 8 at 7 hours; 
2 rabbits, 300 units of Serum 2321  at 7 hours, and 2 rabbits the same dose at 24 
hours; one rabbit, 30 units of Serum 2321  at 7 hours, and one the same dose at 
24 hours. 
The  results are presented in Table I, and show that  all the rabbits 
treated with 300 m.p.u, of Serum 2321  survived, whereas of four rab- 536  ACTION  OF  ANTIPNELrMOCOCCIC  SERUM.  I 
bits treated with 300 m.p.u, of Serum 8, three died.  It thus appeared 
that an equal or similar dose (as regards mouse protective units--the 
unit which is used clinically as the criterion of dosage) of two different 
sera was in one instance fully protective for rabbits and in the other 
practically ineffective.  In addition to the variations in the immuniza- 
tion  procedures  that  were used  in  the  preparation  of the  two  sera, 
there  was  still  another  difference:  standard  Serum  8  contained  the 
300 m.p.u, in 0.38 cc., whereas Serum 2321 contained the same number 
of units  in  5  cc.  The  question  was,  therefore,  whether  the  greater 
effectiveness of Serum 2321  was due to the added intramuscular  in- 
jections  of broth  culture  filtrate  employed in  its  preparation,  or  to 
a factor present in both Serum 2321 and Serum 8, more of which was 
associated with the 300 m.p.u, of the former on account of the larger 
volume of the dose.  In either case, however, this factor would have 
to be of a nature different from the agent which is determined by the 
present method of mouse protection.  By absorbing an antipneumococ- 
cic serum with the homologous organism it is possible to remove almost 
all (about 99.5 per cent) of its mouse protective capacity; it was, there- 
fore,  important  to  determine  whether  the  supernatant  liquid  of  a 
serum  thus  absorbed  could  exert  any  therapeutic  effect in  rabbits. 
The Non-Antibacterial  Therapeutic Factor in Serum  Prepared by In- 
jection of Organisms Intravenously and Broth Culture Filtrate 
Intramuscularly 
In the work done on the r61e of anaerobic toxins in the dermal pneu- 
mococcic lesion of the rabbit (17), as well as in the previous experiment 
it was apparent  that  for every serum there is a  certain  subeffecfive 
dose.  Of a group of rabbits treated with this subeffective dose there 
is at first a sterilization of the blood stream in all; in less than half the 
blood is reinfected whereas in the others it remains sterile; the dermal 
lesion is not markedly influenced; about 60 to  75 per cent die.  Ap- 
proximately half of these rabbits die without reinfection of the blood 
stream and with a sterile postmortem heart's blood culture, but usually 
with a progressively marked lesion.  (Routine postmortem brain cul- 
tures, which were done on all the rabbits reported in these experiments, 
showed that, in the absence of a continued and persistent bacteremia, 
localization  of the infection in  the  central  nervous system was rela- ALBERT B.  SABIN  537 
tively  extremely  rare.)  It  appeared,  therefore,  that  in  these  cases 
death is produced by the absorption of toxins from the local lesion. 
Thus,  it was essential  to determine  whether  a  subeffective  dose of 
serum  could be rendered  effective by the  addition  of that  fraction of 
the  serum  which  remains  after  complete  absorption  with the homol- 
ogous organisms. 
TABLE  II 
The Non-Antibacterial  Therapeutic Factor in Serum Prepared by Injection  of 
Organisms and Broth Culture Filtrates 
Therapy 
Preparation 4 
Preparation  4 
+ 
Absorbed Preparation  4 
Preparation  4 
Preparation  4 
+ 
Absorbed Preparation  4 
Preparation  4 
+ 
Absorbed Preparation  4 
Standard Serum 624 Type I 
Serum 624 
+ 
Absorbed Preparation  4 
Hrs. after  No. of  No. 
Dose  culture  rabbits  used  survived 
0.2  50-100 
0.2  50-100 
0.4  0.4-2.0 
0.4  100-200 
0.4  100-200 
0.6  0.6-3.0 
0.4  100-200 
0.2~  0.25-1.25 
0.2~i  0.25-1.25 
0.2!;  0.25-1.25 
0.3  300 
I 
0.3  3OO 
0.5  0.5-2.5 
0.5  0.5-2.5 
6  9 
6' 
3 
24 
6  5 
6' 
5 
24 
24.  5  5 
48 
72 
6  4 
6  / 
The serum available for this experiment was a concentrated preparation (Prep- 
aration  4)  containing the  total water-soluble and water-insoluble globulin (pre- 
cipitated at 30 to 50 per cent saturation with (NH,)~SO4) of Serum 2321 used in 
the previous experiment.  This preparation contained 250 to 500 m.p.u, per cc. 
Preparation  4 was absorbed with heat-killed,  sedimented pneumococci until no 
further agglutination occurred; when this stage was reached more organisms were 538  ACTION  OF  ANTIPNEUMOCOCCIC  SERUM.  I 
added, and the mixture incubated at 37°C. for 2 hours and kept in the refrigerator 
overnight.  After sedimenting the unagglutinated organisms by thorough centri- 
fugation, the  supernatant  liquid was poured off and  called absorbed Prepara- 
tion 4.  A mouse protection test  2  performed with absorbed Preparation 4 showed 
that it contained 1 to 5 units, indicating  an absorption of about 99.5 per cent of the 
original mouse protective capacity.  In a preliminary experiment a subeffective 
dose of Preparation 4 was determined, then one group of rabbits was injected with 
a subeffective  dose of Preparation 4 at 6 hours, and other groups received, in addi- 
tion to the subeffective  dose at 6 hours, injections of absorbed Preparation 4 at 
24 hours, 48 hours, and .72 hours as shown in Table II. 
The survival rate of the rabbits indicates that 0.2  and 0.4  cc.  of 
Preparation  4  constitute  subeffective doses.  It  is  also  clearly ap- 
parent that the additional injection of 0.6 cc. of absorbed Preparation 
4 at 24 hours or of 0.75 cc. divided in three equal doses at 24 hour iu- 
tervals  rendered  the  subeffective dose  therapeutically effective, all 
the rabbits thus treated having survived.  As confirmatory evidence, 
it was necessary to determine whether absorbed Preparation 4  would 
have a  similar effect when added to a  subeffective dose of standard 
antibacterial serum; i.e., one prepared by immunization with organisms 
only.  The results shown in Table II again indicate that Preparation 
4, after complete absorption with the homologous organisms, contains 
a substance which exerts a definite therapeutic effect on pneumococcus 
infection in  rabbits.  For  convenience,  this  therapeutic  factor was 
called non-antibacterial to indicate merely that it was not absorbed 
or neutralized by the intact homologous organisms, and not to define 
its mode of action.  If this non-antibacterial factor is of the nature 
of an antibody or antitoxin, it apparently must be produced in response 
to some soluble toxic substance, which, however, is not an antigenic 
constituent of the intact organism. 
Can  Pneumococcus  Broth  Culture  Filtrate  Neutralize  the  Non- 
Antibacterial  Factor? 
Since  broth  culture filtrate was  the  additional immunizing agent 
used in the preparation of the serum, which was shown to contain the 
non-antibacterial therapeutic factor, it was important to  determine 
The mouse protection tests reported in these experiments were performed in 
the laboratory of Miss Georgia  Cooper of the New York City Health Department 
Research Laboratories, to whom the author again wishes to express his gratitude. ALBERT  B.  SABIN  539 
whether  or  not  it  would  be  capable  of  neutralizing  this  factor.  It 
seemed that  no  causal  relationship between  the  use  of broth  culture 
filtrate  for  immunization  and  the  presence  of  the  non-antibacterial 
factor  in  the  serum  could  be  established,  unless  such  neutralization 
were  demonstrable. 
1000 cc. of a 24 hour Pneuruococcus Type I broth culture were passed through a 
large Seitz filter.  The filter was then concentrated by a method commonly used 
TABLE  II] 
Effect of Broth Culture Filtrate on Non-Antibacterial Factor 
Therapy 
0.3 cc. Serum 624 (300 units) 
+ 
1.5 cc. absorbed Preparation 4 
0.3 cc. Serum 624 (300 units) 
+ 
Mixture containing 1.5 cc. absorbed 
Preparation 4  and 3.0 cc. alco- 
holic  pneuruococcus  broth  con- 
centrate 
0.3 cc. Serum 624 (300 units) only 
Rabbit 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
Result 
S 
S 
S 
D6* 
S 
D, 
S 
S 
S 
D6 
D3 
D9 
Ds 
Remarks 
Marked  lesion;  bacteremia  con- 
trolled;  postmortem~heart  and 
brain cultures sterile 
Bacteremia uncontrolled 
Marked lesion;  postmortem  heart 
and brain cultures sterile 
cc  ~ 
Marked  lesion;  bacteremia uncon- 
trolled 
* S  -- survived.  D6  =  died 6 days after injection. 
in obtaining diphtheria toxin from broth cultures.  The filtrate was acidified with 
glacial acetic acid and precipitated with 60 per cent alcohol; after remaining in the 
refrigerator overnight, the precipitate was filtered through paper.  It was then 
pressed nearly dry between pieces of filter paper and dissolved in 50 cc. of 0.9 per 
cent NaC1; i.e., in 1/20 the original  volume.  2 cc. of this concentrate injected 
intravenously into two normal rabbits produced no symptoms.  To one part of 
Preparation 4, which previously had been completely absorbed with heat-killed, 540  ACTION  OF ANTIPN-ELrMOCOCCIC  SERUM.  I 
washed  Type I  pneumococci, two parts of the pneumococcus broth concentrate 
were added.  The mixture  was  incubated in the water bath at 37°C. for 2 hours 
and kept in the refrigerator overnight.  A small amount of precipitate had formed; 
this was centrifuged  and the clear supernatant liquid was used for injection into 
rabbits.  Four rabbits  received  a  subeffective  dose  of standard  Serum  624 to- 
gether with 1.5 cc. of absorbed Preparation 4; four other rabbits--Serum 624 and a 
mixture of 1.5 cc. absorbed Preparation 4 treated with 3 cc. of the pneumococcus 
broth concentrate; five rabbits were injected  with the subeffective dose of Serum 
624 only, for control.  All serum was given intravenously 6 hours after the intra- 
cutaneous injection  of the organisms. 
The  results  shown  in  Table  III  indicate  that  the  concentrated 
pneumococcus broth culture filtrate failed to neutralize the therapeutic 
effect of absorbed Preparation 4.  It thus appeared that if the broth 
culture  filtrate  does not neutralize  the  non-antibacterial  therapeutic 
factor, it probably also does not contain its antigen,  and that,  there- 
fore, serum prepared by the standard method of intravenous injection 
of organisms only, should similarly contain this factor. 
Presence of the  Non-Antibacterial  Therapeutic Factor in Serum  Pre- 
pared by the Intravenous Injection of Organisms Only 
The purpose of this experiment was to determine first,  whether or 
not  the  non-antibacterial  therapeutic  factor can  be  demonstrated in 
serum prepared by the intravenous injection of organisms only, and 
second,  whether  it  is  type-,  species-,  or  non-specific.  For  control, 
normal horse serum, and Parker's so called antipneumotoxin, prepared 
by  immunizing  horses  with  the  toxic,  anaerobic,  pneumococcus 
autolysate,  were used. 
The Type I sera were absorbed with Type I, heat-killed, washed pneumococcus 
suspensions;  the heterologous serum, normal horse serum, and Parker's antipneu- 
motoxin were not absorbed with any organisms, because a test showed that they 
contained less than  1 mouse  protective unit per co. for Type I  pneumococcus. 
Four Type I  monovalent sera, one Type II monovalent serum, and  one  normal 
horse serum are included in the tabulation of the results.  The tests were carried 
out at different times on several different groups of rabbits.  To determine whether 
the non-antibacterlal factor could be demonstrated in a serum, other than anti- 
pneumococcic,  one group of rabbits was tested  with a scarlatinal,  antibacterial, 
and antitoxic serum obtained from a horse that at no time had received any injec- 
tions of pneumococci.  The dose varied from 2 to 5 cc. for each serum tested.  The 
results  of all the tests  are summarized in Table IV. ALBERT  B.  SABIN  541 
Of the forty rabbits that were untreated in the various experiments 
none survived.  The striking contrast between the survival rate (29.0 
per cent) of those  receiving the  subeffective dose of Type I  serum 
only with that (81.4 per cent) of the rabbits receiving the additional 
injection of pneumococcus-absorbed Type  I  serum,  indicates  very 
definitely  the  presence  of  a  similar  non-antibacterial,  therapeutic 
factor in serum prepared by the intravenous injection of organisms 
only.  The results with the Type II serum are almost equally striking, 
and  suggest  that  this  non-antibacterial  factor  is  not  type-specific. 
The  apparent  absence  of  the  factor  in  the  antipneumotoxin is  of 
TABLE  IV 
The Non-Antibacterial  Therapeutic  Factor  in  Standard  Antilmeumococcic  Serum 
Serum therapy  No. of rabbits  No. survived  Survival  used 
None  .................................... 
Subeffective dose of Type I  antiserum ....... 
Subeffective  dose  of  Type  I  antiserum  q- 
absorbed Type I  serum .................. 
Subeffeetive dose of Type I  serum 4- heterol- 
ogous  serum Type II ................... 
Subeffective dose of Type I  serum 4- Parker's 
antipneumotoxin ....................... 
Subeffective dose of Type I  serum 4- normal 
horse serum ............................ 
Subeffective dose of Type I  serum 4- scarla- 
tinal antibacterial and  antitoxic  serum... 
40 
31 
43 
17 
22 
10 
10 
0 
9 
35 
12 
6 
4 
3 
~¢cr ccr,/ 
o 
29.0 
81.4 
70.6 
27.3 
40.0 
30.0 
interest with regard to its mode of origin.  The survival rates of the 
rabbits which received the normal horse serum and the scarlatiual, 
antibacterial and antitoxic serum, considering the  smaller number of 
animals, are well within the range of survival of those treated with the 
subeffective dose  only,  the  results  indicating that  this  therapeutic 
factor probably is not non-specific.  Considering the fact that stand- 
ard  antipneumococcic sera  contain, in  addition  to the antibacterial 
antibody,  other therapeutic factors which apparently are  non-anti- 
bacterial,  one can understand more  readily how equal doses, as re- 
gards  mouse protective unit  content, may  vary  in  therapeutic  ef- 
ficiency. ,$42  ACTION OF ANTIPNEIJ~OCOCCIC SERUM.  I 
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Effect  of the  Non-Antibacterial  Therapeutic  Factor  per  Se 
It was essential to determine the effect, if any, of a pneumococcus- 
absorbed serum, that is known to contain the non-antibacterial factor, 
when injected by itself without the addition of a  certain subeffective 
dose of antibacterial serum.  This experiment was expected to yield 
information regarding the r61e of the non-antibacterial factor as well 
as of the mouse protective antibody which is absorbable by the intact 
organism. 
Two preparations were tested:  (a)  absorbed Preparation 4 which has been 
described previously, and (b) absorbed Serum 348, which was an unconcentrated 
monovalent Type I serum of at least 2000 m.p.u, per co., and which after absorp- 
tion with the homologous pneumococcns still contained about 5 m.p.u, per co. 
The dose of absorbed Preparation 4 for each rabbit was 2 cc.; the dose of absorbed 
Serum 348, 0.75 cc.  Three groups of rabbits were tested on different occasions; 
the results are shown in Table V. 
It is necessary to recall that both Preparation 4, which is a concen- 
trated (about 5 times) globulin preparation, and  Serum 348  were  so 
treated  that  the  final  absorbed  preparations  contained no  in  vitro 
demonstrable agglutinins, which involves a  neutralization of the im- 
mune bodies not only by the SSS but by any other antigen that may 
be present on the intact organism.  Whether or not the small amount 
of mouse protective antibody which is still demonstrable in these ab- 
sorbed preparations is of an antibacterial or non-antibacterial nature 
cannot be definitely stated as yet, for it is not improbable that during 
the absorption of antibody an equilibrium may be reached wherein a 
certain small amount of antibody remains uncombined.  Similarly it 
must be stated that the absorbed preparations probably do not con- 
tain the total quantity of non-antibacterial factor that is present in 
the  serum  since  some  of it  may become  non-specifically  adsorbed 
during the precipitation of antibody on the bacteria. 
The results presented in Table V show most interestingly, particu- 
larly in view of the fact that untreated rabbits do not survive with 
this dose of pneumococcus (see Table IV), that a  certain number of 
rabbits is protected by the completely absorbed serum; eight of the 
sixteen rabbits treated with absorbed Preparation 4  and one of the 
five treated with absorbed Serum 348 were fully protected.  A simul- ALBERT B.  SABIN  545 
taneous titration of absorbed Serum 348 administered with a standard 
subeffective dose of Serum 624,  indicates that  approximately 0.5  to 
1.0 cc. is efficient for rendering it effective.  The difference in survival 
rate between the  absorbed  Preparation  4  and absorbed  Serum 348 
groups  appears  to  be a  matter of dosage more as regards the non- 
antibacterial factor than the antibacterial  antibody, for the  rabbits 
that died in the former group had a terminal septicemia, whereas two 
of the rabbits  (Nos.  18 and 20)  in the latter group died without  any 
bacteremia but apparently by absorption  of toxin from the marked 
focal lesions.  Furthermore, it is important to note that in fourteen 
of the first twenty-one rabbits,  the bacteremia was completely con- 
trolled.  Whatever the nature of the residual mouse protective anti- 
body, the amount, contained in the doses that were used, is relatively 
so very small that one is led to think that either only a very minute 
quantity of the antibacterial antibody is required for the control of 
bacteremia, or else that it plays a  secondary r61e particularly  when 
septicemia becomes very marked.  In the last three groups of rabbits 
(Nos. 22  to 36), one observes how with a  relatively standard mouse 
protective unit dose, the bacteremia is more readily controlled as the 
dose of the non-antibacterial factor is increased.  With the larger dose 
of the non-antibacterial factor, as in absorbed Preparation 4, most of 
the rabbits  showed very mild dermal lesions as compared not only 
with control, untreated rabbits but also with those which received an 
insufficient dose.  When one contrasts with this the action of a stand- 
ard subeffective dose that contains a relatively large amount of anti- 
bacterial antibody, in which case the dermal lesions are marked and 
death occurs frequently without bacteremia,  the suggestion is  very 
strong that the ultimate outcome of the infection depends to a great 
extent upon the non-antibacterial therapeutic factor.  The effect of 
the non-antibacterial factor suggests that it opposes, in some way as 
yet unknown,  the action of the products of infection which locally 
are  responsible  for  a  marked  dermal  lesion,  and  systemically are 
probably the cause of death. 
DISCUSSION 
The work reported in this communication  is in line with an attempt 
to determine  the mechanism  of death and recovery  in pneumococcus 546  ACTION  OF  ANTIPNEIIMOCOCCIC  SERUM.  I 
infection.  The r61e of the antibacterial antibodies, which are capable 
of combining with the various constituents of the bacterial protoplasm, 
is ultimately, as was pointed out by Bull, to enhance phagocytosis of 
the organisms by cells of the blood and tissues.  With the thought that 
the mere multiplication  of organisms  as  so  many microscopic par- 
ticles cannot logically be the cause of death, the view that phagocy- 
tosis is the chief factor which determines death or recovery appears 
to be unsatisfactory in many respects.  The  constituents which are 
isolated from virulent pneumococci in vitro  and against which anti- 
bodies are demonstrable in the standard antipneumococcic sera,  are 
non-toxic; yet when the intact, living  organisms are introduced into 
the body of a  susceptible animal, a  most potent toxin is apparently 
elaborated.  The question arises, therefore, whether antipneumococcic 
serum is effective only when through preventing the multiplication of 
the organisms it also prevents the formation of a  lethal amount of 
toxin, or whether it possesses an action against this toxin as well. 
Since in the method of mouse protection, which is at present used 
as  the  criterion  for  determining the  potency  of  antipneumococcic 
sera, the serum is injected simultaneously with a relatively very small 
number of organisms into the same body cavity, the function which 
is primarily involved is  that which brings about their phagocytosis, 
and prevents  the multiplication of organisms  to  the  extent that  a 
lethal dose of toxin is not produced.  For this reason this method was 
deemed unsuitable in the present study.  The dermal pneumococcus 
lesion of the rabbit was chosen because it provided a focus where the 
organisms may be localized and from which, under conditions which 
are unsuitable for the systemic multiplication of the bacteria, sufficient 
toxin may be absorbed to cause death of the animal. 
The first serum to  be investigated was one prepared by the late 
Dr.  E.  J'.  Banzhaf, who immunized several horses not only by the 
intravenous injection of sedimented pneumococci (which is the routine 
practice), but also by the additional intramuscular injection of broth 
culture filtrates.  Preliminary experiments showed that when certain 
similar  doses,  as  regards  mouse  protective  potency,  of  Banzhaf's 
serum and one prepared by the standard procedure, were tested on 
rabbits  with  the  experimental  dermal  pneumococcus infection,  the 
former was found to be fully protective and the latter practically in- ALBERT  B.  SABIN  547 
effective.  It was thus apparent that the protective effect did not de- 
pend only on the number of mouse protective units and that some 
factor which was not determined by the mouse protection test, was 
present in one serum and absent in the other, or else present in both, 
but  in  different concentrations.  The  subsequent  experiments were 
designed to determine whether this factor was of antibacterial or non- 
antibacterial nature.  By absorbing an antipneumococcic serum with 
a  heat-killed suspension of homologous pneumococci it is possible to 
remove almost all (about 99.5 per cent) of its mouse protective antibody. 
When this antibody was absorbed from the serum, prepared by im- 
munization with organisms and broth culture filtrates, and the remain- 
ing supernatant liquid was administered with a subeffective dose (see 
Table II) of the original serum, it was found that this combined therapy 
proved  fully effective.  It  appeared,  therefore,  that  the  difference 
between an effective and ineffective dose was not only the antibacterial 
antibody (i.e.  that which is absorbed with the intact organisms) but 
also another factor which is apparently non-antibacterial.  Further- 
more, it was shown that a certain dose of such an absorbed preparation 
was by itself therapeutically effective in about half the treated rabbits. 
In the same experiment an analysis of the course of the bacteremia 
in the various rabbits indicated that either only a minute amount of 
the antibacterial antibody is required for the control of the bacteremia 
or else that it plays merely a secondary r61e only when the septicemia 
becomes very marked.  These results again pointed to the fact that 
the ultimate outcome of the infection is dependent to a  considerable 
extent upon the non-antibacterial therapeutic factor. 
However, no definite causal relationship  could be  established be- 
tween the additional injections of broth culture filtrates for immuniza- 
tion  and the presence in  the serum of the non-antibacterial factor, 
because (a) a concentrated preparation of broth culture filtrate failed 
to neutralize it, and (b) standard serum, prepared by the intravenous 
injection of  sedimented organisms only,  also  contained  this  factor. 
It was further demonstrated that the non-antibacterial factor is not 
type-specific, and that it is probably species-specific.  If this factor 
is of the nature of an antibody or an antitoxin, it  must  necessarily 
have its corresponding antigen.  Such an antigen, by the very defini- 
tion of the non-antibacterial factor, is not present in  the intact or- 548  ACTION  OF  ANTIPNEUMOCOCCIC  SERUM.  I 
ganism; a  concentrated broth culture filtrate did not contain it; and 
judging from the results obtained in these experiments, it is apparently 
also  absent  in  the  in  vitro  anaerobic  autolysates of pneumococcus; 
however, it is not inconceivable that it may originate from the pneumo- 
coccus in vivo.  From this point of view, it is interesting to consider 
the recently proposed conception of Curphey and Baruch (18).  On 
purely theoretical grounds, they proposed the possibility that the im- 
mune bodies developed in the course of lobar pneumonia include anti- 
bodies which are formed as a  result of the products of tissue  cell  de- 
struction either per se or in combination with certain bacterial products. 
On the basis of this conception, they have prepared antipneumococcic 
serum by immunization with pleural  exudates from pneumococcus- 
infected horses.  In comparing (19)  similar doses, as regards mouse 
protective  units,  of  their  serum  with  that  of  standard  serum, 
using the dermal pneumococcus infection in rabbits,  they found  the 
former therapeutically more effective; however,  since standard  sera 
were shown to contain a  non-antibacterial factor, and on account of 
the fact that the volume of the doses of the two sera was not taken 
into consideration, one cannot definitely assign the greater therapeutic 
effectiveness to  the mode of immunization.  The possibility,  never- 
theless, remains and deserves further investigation. It is also interesting 
to correlate the non-antibacterial therapeutic factor with Tillett's (20) 
observations on the production of immunity in rabbits  against  viru- 
lent strains by injections of R  pneumococci; this immunity was not 
type-specific, and the serum of rabbits  thus immunized, although it 
contained no demonstrable mouse protective antibody, was, neverthe- 
less, capable of protecting normal rabbits  against  virulent  Types  I, 
II, and III  pneumococci. 
The fact, that antipneumococcic serum was shown to contain a thera- 
peutically  active  non-antibacterial  factor,  may have  an  important 
bearing on the serum treatment of pneumococcus pneumonia in man, 
and suggests many new problems some of which have been investigate d 
and will be reported in the next communication. 
CONCLUSIONS 
1.  Antipneumococcic serum contains in addition to the antibodies 
against the various bacterial constituents, a  non-antibacterial thera- 
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2.  The non-antibacterial factor has been separated from the anti- 
bacterial  antibodies  by  absorption  with  homologous,  heat-killed, 
virulent pneumococci. 
3.  The non-antibacterial factor is not type-specific; it is probably 
species-specific; it is not neutralized  by  concentrated pneumococcus 
broth culture filtrate. 
4.  The therapeutic effect of the non-antibacterial factor was demon- 
strated on the experimental, dermal pneumococcus infection of rabbits; 
this  effect is  demonstrable when it  is  administered per se or in con- 
junction with a  certain subeffective dose of serum. 
5.  Evidence is presented for the assumption that the ultimate out- 
come of pneumococcus infection depends to a considerable extent upon 
this non-antibacterial factor. 
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